SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
尧尧
Lv1
65 积分
2021-03-25 加入
最近求助
最近应助
互助留言
Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives
1个月前
已完结
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere
1个月前
已完结
Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
1个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
1个月前
已完结
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
1个月前
已完结
Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures
1个月前
已完结
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non–organ-confined Upper Tract Urothelial Carcinoma
1个月前
已完结
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients
1个月前
已完结
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
1个月前
已完结
Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
1个月前
已完结
没有进行任何应助
速度真快,感谢
1个月前
感谢
1个月前
感谢
1个月前
速度真快
1个月前
帮大忙了
1个月前
点赞
1个月前
速度真快
1个月前
速度真快
1个月前
帮大忙了
1个月前
已找到【积分已退回】
1个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论